Antisense, RNA

Analytical development services for oligonucleotides: For oligo-based drugs, our capabilities range from GLP bioanalysis to GLP/cGMP characterisation. We support product development, from quality control testing of amidite starting materials and early stage product characterization through to GMP batch rele...

WuXi STA has an integrated Oligo API process R&D and manufacturing platform from preclinical to commercial, operating at our US FDA inspected integrated process R&D and manufacturing facility based in Changzhou, China. We support the development and manufacture of a variety of oligonucleotide modaliti...

We provide a wide range of discovery and development services for New Biological Entities (NBEs) from our state-of-the-art facility located in Hyderabad, India. At the core of NBE services is a talented team of scientists experienced in the design and delivery of a range of advanced therapeutic modalities suc...

Characterization and analysis of mRNA supporting vaccine and therapeutic development, including assessing clinical translation efficiency and immunogenicity. At our GLP / GCP / GMP laboratories, scientists can test a mRNA drug substance or drug product to help you confidently assess batch to batch manufactu...

Combination therapy of TGF-β2 Targeting Antisense Oligonucleotide (TASO) + IL-2

ATB-301 is a new drug candidate for combined anti-cancer treatment of TGF-β selective inhibitor, TASO and IL-2.

In-vitro : Verified synergistic effect by TASO+IL-2 combination therapy on breast c...